Table 3.

Radiochromatographic analyses of urine and feces following a single oral administration of [¹⁴C]dolutegravir to healthy male human subjects at a target dose of 20 mg (80 μCi)

Peak ID	Retention time (min)	% Matrix radioactivity (mean ± SD; n = 6) [% dose (mean ± SD)]a
		Urine	Feces
M1	12.2–12.8	11.8 ± 2.0 [3.6 ± 0.9]	2.2 ± 0.7 [1.3 ± 0.4]
M2	24.4–24.8	62.5 ± 3.9 [18.9 ± 3.0]	ND
M3b	37.2 + 40.2	10.1 ± 2.8 [3.0 ± 0.9]	ND
M4	24.0–24.4	NQ	3.1 ± 1.3 [1.8 ± 1.3]
Dolutegravir	44.4	2.2 ± 0.2 [0.7 ± 0.1]	89.1 ± 3.3 [53.1 ± 4.4]
Total radioactive material assigned		86.6 ± 2.3 [26.2 ± 3.9]	94.4 ± 3.5 [56.3 ± 3.9]
% Dose in matrix pool analyzed		30.2 ± 4.3	59.7 ± 5.5
Total % dose excreted in matrix (all time points)		31.6 ± 4.6	64.0 ± 4.7

^aND, not detected (below lower limit of detection of 3 times background); NQ, not quantifiable (radioactivity was present at this retention time, but the concentration was too low for complete structural identification).

^bThe reported values for M3 are the sum of both diastereomers.